(R)-4-Methyloxazolidin-2-one → (R)-3-{5-[4-(5-ethyl-3-methylpyridin-2-yl)piperazine-1-carbonyl]-3-methylpyridin-2-yl}-4-methyloxazolidin-2-one
反応式
[CH2:1]([C:3]1[CH:4]=[C:5]([CH3:25])[C:6]([N:9]2[CH2:14][CH2:13][N:12]([C:15]([C:17]3[CH:18]=[N:19][C:20](F)=[C:21]([CH3:23])[CH:22]=3)=[O:16])[CH2:11][CH2:10]2)=[N:7][CH:8]=1)[CH3:2].[CH3:26][C@@H:27]1[CH2:31][O:30][C:29](=[O:32])[NH:28]1>>[CH2:1]([C:3]1[CH:4]=[C:5]([CH3:25])[C:6]([N:9]2[CH2:14][CH2:13][N:12]([C:15]([C:17]3[CH:22]=[C:21]([CH3:23])[C:20]([N:28]4[C@H:27]([CH3:26])[CH2:31][O:30][C:29]4=[O:32])=[N:19][CH:18]=3)=[O:16])[CH2:11][CH2:10]2)=[N:7][CH:8]=1)[CH3:2]参加物
3
実験手順
By reaction and treatment in the same manner as in Example 240 and using [4-(5-ethyl-3-methylpyridin-2-yl)piperazin-1-yl](6-fluoro-5-methylpyridin-3-yl)methanone (440 mg) described in Preparation Example 149 and (R)-4-methyloxazolidin-2-one (261 mg) described in Preparation Example 25, the title compound (173 mg) was obtained.